Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
MDS patients who have failed prior HMA therapy selected as first indication to advance into Phase 2 3 mg/kg and 6 mg/kg doses selected in accordance with FDA’s Project Optimus initiative guidancePhase 2 part of the study will recruit 32 HMA-failed MDS patients for 1:1 dose randomization with possible data release after 20 patients have received more than two treatment cycles Company announcement, Inside Information TURKU, Finland and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) Faron Pharmaceutical
06.11.2023 - MDS patients who have failed prior HMA therapy selected as first indication to advance into Phase 2 3 mg/kg and 6 mg/kg doses selected in accordance with FDA’s Project Optimus initiative guidancePhase 2 part of the study will recruit 32 HMA-failed . Seite 1
Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.